TaiGen Biopharmaceuticals Holdings Limited

Total Valuation

TaiGen Biopharmaceuticals Holdings Limited carries a market capitalization of 6.55B, placing it among publicly traded companies globally. Its enterprise value stands at 8.58B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

TaiGen Biopharmaceuticals Holdings Limited currently has 711.83M shares outstanding.

Valuation Ratios

TaiGen Biopharmaceuticals Holdings Limited trades at a trailing price-to-earnings ratio of 211.62. The price-to-sales ratio is 36.85, and the price-to-book ratio stands at 15.67.

Enterprise Valuation

On an enterprise value basis, TaiGen Biopharmaceuticals Holdings Limited trades at an EV/EBITDA multiple of 123.68 and an EV/FCF ratio of 320.93. The EV/Sales ratio of 33.08 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 123.68 provides insight into valuation relative to core operating earnings.

Financial Position

TaiGen Biopharmaceuticals Holdings Limited maintains a current ratio of 13.48, meaning it holds 13.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.58, indicating elevated leverage, while an interest coverage ratio of 41.68 demonstrates strong ability to service its debt obligations.

Financial Efficiency

TaiGen Biopharmaceuticals Holdings Limited posts a return on equity of 7.25 and a return on invested capital of 4.82.

Taxes

Over the trailing twelve months, TaiGen Biopharmaceuticals Holdings Limited has paid 12.26M in income taxes, reflecting an effective tax rate of 21.35.

Stock Price Statistics

TaiGen Biopharmaceuticals Holdings Limited's stock has gained approximately 8.23529% over the past 52 weeks. The 50-day moving average sits at 9.13, while the 200-day moving average is 10.66.

Income Statement

Over the trailing twelve months, TaiGen Biopharmaceuticals Holdings Limited generated 259.47M in revenue and converted that into 45.18M in net income, yielding earnings per share of 0.06. EBITDA reached 69.40M, while operating income came in at 69.40M.

Balance Sheet

TaiGen Biopharmaceuticals Holdings Limited holds 1.03B in cash and equivalents against 49.22M in total debt, resulting in a net debt position of -110.09M. Total book value stands at 609.95M, with working capital of 1.04B providing operational flexibility.

Cash Flow

TaiGen Biopharmaceuticals Holdings Limited produced 20.93M in operating cash flow over the past twelve months. After subtracting -4.50M in capital expenditures, free cash flow totaled 16.42M - equivalent to 0.02 per share.

Margins

TaiGen Biopharmaceuticals Holdings Limited operates with a gross margin of 93.00, reflecting its pricing power and cost economics. The operating margin of 26.74 and net profit margin of 17.41 provide insight into operational efficiency.

Dividends & Yields

Scores

TaiGen Biopharmaceuticals Holdings Limited posts an Altman Z-Score of 64.33, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.